Free tool
FAERS Monitor: Cometriq
Last checked: Nov 21, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 203756 or its brand name (Cometriq, Cabozantinib S-Malate). Reports on generic versions are filed under their own applications.
Reports
5,563
Serious
3,912
70% of reports
Hospitalization
2,447
Death reported
976
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use1,109
- diarrhoea1,034
- fatigue713
- nausea516
- malignant neoplasm progression477
- decreased appetite452
- asthenia333
- stomatitis332
- weight decreased329
- death317
- vomiting301
- palmar-plantar erythrodysaesthesia syndrome268
- hypertension259
- pain in extremity227
- rash205
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 214 |
| 2014 | 304 |
| 2015 | 304 |
| 2016 | 147 |
| 2017 | 518 |
| 2018 | 626 |
| 2019 | 505 |
| 2020 | 419 |
| 2021 | 605 |
| 2022 | 637 |
| 2023 | 502 |
| 2024 | 288 |
| 2025 | 285 |
| 2026 | 206 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,596 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| diarrhoeaSignal | 1,034 | 6.1 | 5.7 | 4,499 |
| off label useSignal | 1,109 | 4.8 | 4.5 | 3,465 |
| fatigueSignal | 713 | 3.5 | 3.2 | 1,294 |
| astheniaSignal | 333 | 3.4 | 3.0 | 556 |
| nauseaSignal | 516 | 2.5 | 2.3 | 465 |
| vomitingSignal | 301 | 2.4 | 2.2 | 255 |
| rash | 205 | 1.8 | 1.6 | 71 |
| death | 317 | 1.4 | 1.3 | 36 |
| malignant neoplasm progression | 477 | 0.0 | 0.0 | 1,801,072 |
| decreased appetite | 452 | 0.0 | 0.0 | 1,706,476 |
| stomatitis | 332 | 0.0 | 0.0 | 1,252,419 |
| weight decreased | 329 | 0.0 | 0.0 | 1,241,067 |
| palmar-plantar erythrodysaesthesia syndrome | 268 | 0.0 | 0.0 | 1,010,257 |
| hypertension | 259 | 0.0 | 0.0 | 976,203 |
| pain in extremity | 227 | 0.0 | 0.0 | 855,123 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.